Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $12.1252W HIGH $35.34
Volume
608.63 K
Value Traded
12.10 M
Short % Float
10.19%
+10.99%Week
-2.79%1 Month
+14.57%3 Month
+25.85%6 Month
-57.29%5 Year
-57.29%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.15 B
EPS (TTM)
-1.68
P/E Ratio
-
Ent. Value
181.82 M
Total Shares
61.14 M
Float Shares
57.83 M
Insiders
5.41%
Institutions
96.21%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
JANX Catalyst Timeline
Dated clinical, regulatory and corporate events for Janux Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Janux Therapeutics, Inc.
148Total events
4Upcoming
18Tier-1 (high impact)
2021 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedJANX013Trial
First patient dosed in Phase 1 study of JANX013 in mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Trial InitiationJANX013Trial
Initiation of Phase 1 clinical program for JANX013
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX007Trial
Expansion cohort of JANX007 in combination with darolutamide actively enrolling
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Trial InitiationJANX011Trial
JANX011 Phase 1 study ongoing in healthy volunteers
autoimmune diseasessource ↗
▼Program DiscontinuationJANX008DiscontinuedCorporate
Discontinued development of JANX008 following Phase 1a completion
cancersource ↗
▲Development Candidate NominationPreclinical
Development candidate nomination under Bristol Myers Squibb collaboration
solid tumorsource ↗
▲Partnership / LicenseCorporate
Collaboration and exclusive worldwide license agreement with Bristol Myers Squibb
●Quarterly UpdateCorporate
Janux reports second quarter 2026 financial results and business highlights
▲Trial InitiationJANX014Trial
Clinical initiation of JANX014
metastatic castration-resistant prostate cancersource ↗
▲Trial InitiationJANX013Trial
Advancement of JANX013 toward the clinic
metastatic castration-resistant prostate cancersource ↗
▲Trial InitiationJANX011Trial
Ongoing Phase 1 clinical study of JANX011 in healthy volunteers
autoimmune diseasessource ↗
▼Trial DiscontinuedJANX008DiscontinuedTrial
Discontinuation of JANX008 clinical development
solid tumorssource ↗
▲First Patient DosedJANX014Trial
First participant dosed in Phase 1 study of JANX014
metastatic castration-resistant prostate cancer (mCRPC)source ↗
▲Development Candidate NominationPreclinical
Development candidate nomination under Bristol Myers Squibb collaboration
solid tumorsource ↗
●Enrollment UpdateJANX007Trial
JANX007 Phase 1b enrollment continues in taxane-naïve mCRPC cohorts
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX014Trial
JANX014 Phase 1 study continues enrolling patients with mCRPC
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX011Trial
JANX011 Phase 1 healthy volunteer study continues enrolling
autoimmune diseases (healthy volunteers)source ↗
▲First Patient DosedJANX011Trial
First participant dosed in Phase 1 study of JANX011
autoimmune diseasessource ↗
▲Partnership / LicenseCorporate
Collaboration and exclusive worldwide license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors
solid tumorssource ↗
▲Partnership / LicenseCorporate
Announced collaboration and exclusive worldwide license agreement with Bristol Myers Squibb
solid tumorsource ↗
▼Program DiscontinuationJANX008DiscontinuedCorporate
Discontinued development of JANX008 following Phase 1a completion
cancersource ↗
▲Development Candidate NominationPreclinical
Development candidate nomination under BMS collaboration triggered $35M milestone
solid tumorsource ↗
▲Enrollment CompleteJANX008DiscontinuedTrial
Phase 1a dose-escalation portion completed
multiple solid tumorssource ↗
◆Oral PresentationJANX007Presentation
Virtual event to discuss updated interim data for JANX007
mCRPCsource ↗
●Enrollment UpdateJANX007Trial
Enrollment ongoing for JANX007 Phase 1 trial
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX008DiscontinuedTrial
Enrollment ongoing for JANX008 Phase 1 trial
advanced or metastatic solid tumorssource ↗
▲Topline ReadoutJANX007Clinical Data
Updated Phase 1 interim clinical data for JANX007 in mCRPC
mCRPCsource ↗
◆Oral PresentationJANX007Presentation
Additional data from JANX007 to be presented at future Janux events in Q4 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationJANX008DiscontinuedPresentation
Additional data from JANX008 to be presented at future Janux events in Q4 2025
advanced or metastatic solid tumorssource ↗
▲First Patient DosedTrial
First patient dosed in lead collaboration program triggers $10 million milestone payment from Merck
▲Milestone PaymentCorporate
Clinical milestone payment of $10 million from Merck triggered by first patient dosed
▲Trial InitiationJANX007Trial
Phase 1b expansion study initiated with JANX007 in taxane-naive mCRPC patients
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX007Trial
Enrollment ongoing for JANX007 Phase 1 trial
metastatic castration-resistant prostate cancer (mCRPC)source ↗
●Enrollment UpdateJANX008DiscontinuedTrial
Enrollment ongoing for JANX008 Phase 1 trial
advanced or metastatic solid tumorssource ↗
▲Full ResultsJANX007Clinical Data
Updated JANX007 data from Phase 1a dose escalation as of April 21, 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationJANX007Presentation
Additional data from JANX007 to be presented at future Janux events in H2 2025
metastatic castration-resistant prostate cancer (mCRPC)source ↗
◆Oral PresentationJANX008DiscontinuedPresentation
Additional data from JANX008 to be presented at future Janux events in H2 2025
advanced or metastatic solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How JANX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | JANX007 | Phase 1 interim results | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C48 / 100
Pipeline Score
$844M
Pipeline Value
Fair Value
Valuation Signal
5
Drugs Scored
0.8x
rNPV / MCap
Top 22%
Micro Cap(rank 146 of 658)
Percentile Rank
Janux Therapeutics, Inc. carries a moderate pipeline score (48/100), with $2.1B risk-adjusted pipeline value, led by JANX007 in Prostate Cancer (Phase 1), across $59B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| JANX014 Monoclonal antibodyNCT07545811 | Prostate Cancer | Phase 1 | RECRUITING | 43 | Mar 1, 2029 |
Clinical Trial Results
Readouts, endpoints and source filings for every JANX program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Campbell David AlanDirector, Officer (President and CEO) | Option | 7,000 388,582 held | $4.21 | 07/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in JANX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 1.5 % (-6.3 %) | 171.87 M | 11.19 M |
JANX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How JANX ranks across every disease it competes in
Competitive Position is a premium feature
See how JANX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialJANX News
JANXJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
Janux Therapeutics has announced the dosing of the first patient in its Phase 1 clinical trial for JANX013, a bispecific immunotherapy targeting PSMA in metastatic castration-resistant prostate cancer. This trial aims to evaluate the safety and efficacy of JANX013, initially in combination with JANX007. The development marks a significant step forward for the company.
Read more →JANXJanux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for Q2 2026, highlighting ongoing progress in its clinical portfolio. The company is actively preparing for several upcoming milestones, indicating a robust operational focus. CEO David Campbell emphasized the execution of their strategic plans during this quarter.
Read more →JANXJanux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
Janux Therapeutics has reported its financial results for the first quarter of 2026. The report includes various business highlights, although specific details about financial performance or strategic initiatives are not provided in the article. The overall tone remains neutral without significant positive or negative developments.
Read more →JANXJanux Therapeutics Announces Discontinuation of JANX008 Clinical Development
Janux Therapeutics has announced the discontinuation of its JANX008 clinical development after evaluating the Phase 1a study results. Despite some durable responses in select patients, the overall activity was not sufficient to justify further investment. The company will redirect resources to other pipeline opportunities while continuing to develop its broader TRACTr platform.
Read more →JANXJanux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
Janux Therapeutics has initiated a Phase 1 clinical trial for JANX014, a T cell engager targeting metastatic castration-resistant prostate cancer (mCRPC). This trial marks the first patient dosing and aims to assess the safety and efficacy of the treatment. The company is building on its existing prostate cancer programs, including JANX007, which has shown promising early results.
Read more →JANXJanux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
Janux Therapeutics has announced the nomination of a development candidate under its collaboration with Bristol Myers Squibb. This milestone achievement has triggered a $35 million payment. The candidate utilizes Janux's TRACTr platform to target a specific solid tumor antigen, marking a significant advancement in their immunotherapy pipeline.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for Q4 and full year 2025, highlighting significant advancements in its clinical pipeline, particularly with JANX007 and JANX008. The company has formed a strategic collaboration with Bristol Myers Squibb, which is expected to provide capital and validate its platform. Janux is focused on expanding its product candidates and enhancing its clinical strategy for future growth.
Read more →JANXJanux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has announced the dosing of the first participant in a Phase 1 clinical study of JANX011, a bispecific targeting CD19 for autoimmune diseases. This study aims to evaluate the safety and pharmacodynamics of JANX011, which has shown promising preclinical results. The ARM platform may offer advantages over conventional therapies, with potential applications in hematologic malignancies as well.
Read more →JANXJanux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Janux Therapeutics has appointed Dr. William Go as Chief Medical Officer, effective January 26, 2026. Dr. Go, who succeeds Zachariah McIver, brings over 20 years of experience in hematology and oncology. His appointment comes as Janux advances its clinical pipeline and regulatory efforts, focusing on innovative immunotherapy solutions.
Read more →JANX▲ +14.1%on this news
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
Janux Therapeutics has entered into a collaboration and exclusive license agreement with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors. This partnership aims to leverage Janux's proprietary technology and Bristol's expertise to accelerate the delivery of new treatments. Janux will handle preclinical development, while Bristol will manage IND submission and commercialization, with potential financial benefits of up to $800 million.
Read more →JANXJanux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
Janux Therapeutics has provided an update on its ongoing Phase 1 study of JANX008, an EGFR-targeted TRACTr for various solid tumors. The study has completed its dose-escalation phase and is now moving into expansion cohorts for further evaluation. Janux plans to share more updates as the study progresses.
Read more →JANX▼ -53.3%on this news
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
Janux Therapeutics announced positive interim data from its Phase 1 clinical trial of JANX007, a PSMA-directed TRACTr for mCRPC. The trial showed durable responses and a manageable safety profile, with high PSA response rates. The company is exploring further applications of JANX007 in earlier-line treatments and in combination therapies.
Read more →JANXJanux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
Janux Therapeutics reported its third quarter 2025 financial results, showing ongoing enrollment in two clinical trials for its drug candidates JANX007 and JANX008. The company reported a strong cash position of $989 million, aiding its operational capabilities. Over the past year, Janux has reduced its net loss, which may reflect improved financial management. However, increased research and development costs and the challenges of upcoming clinical trials present risks to the company’s outlook.
Read more →JANX▼ -6.6%on this news
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
Janux Therapeutics reported its financial results for Q2 2025, highlighting advancements in its TRACTr, TRACIr, and ARM pipelines, which target various cancers and autoimmune diseases. Key updates include ongoing enrollments in the clinical trials for JANX007 and JANX008, with first patient dosing in collaboration with Merck generating a $10 million milestone payment. Despite a strong cash position of $996 million, the company reported a net loss of $33.9 million for the quarter, reflecting increased research and development costs compared to the previous year.
Read more →JANXJanux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
Janux Therapeutics reported its first-quarter 2025 financial results, highlighting the initiation of a Phase 1b expansion study for its drug JANX007 in patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC). Updated results from the Phase 1a trial showed promising median progression-free survival, with median rates slightly improving. The company maintains a robust financial position, with over $1 billion in cash and equivalents, and plans to present additional data later in the year.
Read more →JANXJanux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
Janux Therapeutics reported positive financial results and business highlights for Q4 and full year 2024. The company presented encouraging Phase 1 clinical trial data for its drug JANX007, showing significant prostate-specific antigen response rates and durable declines in mCRPC patients. With a strong cash position of $1.03 billion, Janux is positioned to advance its clinical development plans and upcoming R&D activities slated for 2025. Progress on clinical trials for both JANX007 and JANX008 is ongoing, with further data updates expected next year.
Read more →JANX▲ +49%on this news
Janux Therapeutics Announces Proposed Public Offering
Janux Therapeutics has announced a proposed public offering of $300 million in shares of its common stock, with an additional option for underwriters to purchase up to $45 million more. The company plans to use the proceeds to advance its clinical development programs. Janux's proprietary technology focuses on tumor-activated immunotherapies, which aim to treat various solid tumors while minimizing safety concerns. However, the offering's success hinges on market conditions and other factors.
Read more →JANX▼ -11.1%on this news· ran to +47% by day 3shared move
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC • Emerging JANX007 data demonstrated subs
Janux Therapeutics has selected doses for Phase 1b expansion trials of its JANX007 therapy, which has shown substantial clinical activity in patients with metastatic castration-resistant prostate cancer (mCRPC). In a Phase 1a trial, 100% of patients exhibited PSA50 declines, with a majority achieving deeper and durable responses. The safety profile of JANX007 appears favorable, primarily involving low-grade adverse events. As Janux moves forward into more advanced trials, they highlight a substantial unmet need for this patient population.
Read more →About Janux Therapeutics, Inc.
Headquarters10955 VISTA SORRENTO PARKWAY, SAN DIEGO, CA, 92130
BIOPHARMAWATCH ELITE PLUS
Trade the next JANX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime